Next generation VLP-based prophylactic and therapeutic vaccines with improved efficacy and safety profile
High-yield, fast and cost-effective VLP production technology for the development of novel prophylactic and therapeutic vaccines
Opportunities to achieve personal and professional goals as valued contributors to global public health
Notice that the received the TIPS program grant as follows. Project titleTIPS ProgramPrimary organizationInThera IncDevelopment period2017.06.01. ~ 2019.05.31. Contribution from government500,000,000 KRWInvestment 100,000,000 KRW
InThera Inc. aims to develop and deliver the next generation virus-like particle (VLP)-based prophylactic and therapeutic vaccines with improved efficacy and safety profile against emerging/re-emerging viral infections of global concern.
InThera Inc. established a novel E.coli - based VLP production platform which offers an efficient, homologous, stable and highly immunogenic products and significantly reduce the scaling-up time and complexity. The endeavor will heighten the translation opportunity for unmet-need vaccines and provide the alternative means for the delivery of safer and more effective version of previously licensed vaccines
Through the use of our platform technology, InThera Inc. will provide more safe and innovative solutions against emerging/re-emerging viral infections.
Emerging viruses pose a major threat to global public health and economic burdens. And yet, the conventional cell culture often fails to develop and deliver sufficient vaccine in a timely manner. As an alternative to cell-culture based vaccine, VLPs are considered as a high priority vaccine strategy. InThera aims to develop unmet-need prophylactic and therapeutic vaccines against the emerging viral infections, in which vaccine development has been hampered due to the lack of the proper culture system for the virus of concern.more
In response to the strong growth and demands of veterinary vaccines for livestock and companion animal, InThera develop and delivery of more safe, effective and affordable version of previously licensed inactivated vaccines.more